Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
US7211557B2 · kind B2 · utility
91Cited by
8References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 5, 2003 |
| Grant date | May 1, 2007 |
| Priority date | — |
| Expiry date | May 18, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.